Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Genesys/Takeda: Not Quite Validation for Cell Therapy

This article was originally published in Start Up

Executive Summary

After enduring years of investor and partner skepticism, cell therapy has finally gotten what should be its validating deal: Cell Genesys's $50-million-upfront worldwide alliance with Takeda for Phase III GVAX prostate. But none of the companies who discussed licensing the product focused on the fact that it is a cellular therapy , regarding it as a prostate cancer treatment that happens to be a cellular therapy. Until GVAX delivers definitive and positive Phase III data, other cell therapy companies (like Dendreon and Antigenics) shouldn't get their partnering hopes up.

You may also be interested in...



Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO

Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in

Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO

Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in

In Immunotherapy, Finally time for T Cells?

Immunotherapy has seen its share of failures in recent months, but T-cell oriented therapies are by no means dead in the water and therapeutic cancer vaccines continue to attract funding. This month START-UP profiles three companies that nevertheless have been able to attract funding . They aim to avoid the difficulties that have sunk other efforts to commercialize immunotherapies. The firms are transplanting T cells along with same-donor bone marrow to fight infection, delivering powerful cytokines and other therapeutic payloads via T-cell receptor targeting, and genetically enhancing the ability of T-cell receptors to recognize antigens before growing those T cells in culture and re-infusing them into a patient's body.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel